Company Encyclopedia
View More
name
Oragenics
OGEN.US
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and lantibiotics. The company was formerly known as Oragen, Inc.
1.946 T
OGEN.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Oragenics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    OGEN
    -1.49%
    LB filings·
    US
    OGEN
    -1.49%

    Oragenics Regains NYSE Compliance After Public Offering

    Oragenics (OGEN) has regained compliance with NYSE American listing standards after a $16.5 million public offering in July 2025. The company settled a $700,000 dispute with Ladenburg Thalmann & Co. related to an investment banking agreement. Despite this, Spark's AI Analyst rates OGEN as Underperform due to significant financial distress, negative equity, and cash flow issues, leading to a low performance score. Oragenics is advancing its lead candidate, ONP-002, for treating traumatic brain injuries into Phase IIa trials in Australia.

    Tip Ranks·
    US
    OGEN
    -1.49%
    Tip Ranks·
    US
    OGEN
    -1.49%

    Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing

    Oct 21 (Reuters) - Oragenics Inc (OGEN.A) :* ORAGENICS INC - ENTERS SETTLEMENT AGREEMENT WITH LADENBURG THALMANN - SEC FILING Source text: Further company coverage: (OGEN.A)

    Reuters·
    US
    OGEN
    -1.49%
    Reuters·
    US
    OGEN
    -1.49%

    Receptor.AI Partners with Oragenics to Accelerate AI-Guided Discovery of Neurological Therapeutics

    Receptor.AI has partnered with Oragenics to enhance the discovery of neurological therapeutics using AI technology. The collaboration will utilize Receptor.AI's AI platform to analyze molecules from Oragenics and generate hypotheses on receptor binding profiles for disorders like Alzheimer's and PTSD. The partnership aims to improve early-stage discovery efficiency through structure-based predictions and extensive profiling of compounds. Both companies believe this collaboration will streamline resources and accelerate the identification of new treatments for neuropsychiatric conditions.

    PharmaVoice·
    US
    OGEN
    -1.49%
    PharmaVoice·
    US
    OGEN
    -1.49%

    Oragenics partners Receptor.AI for brain health candidate portfolio

    Oragenics has partnered with Receptor.AI to accelerate the development of a new pharmaceutical candidate portfolio focused on brain health. This collaboration will utilize AI modeling to optimize receptor binding profiles for new compounds added in 2023. The partnership aims to enhance lab validation processes and support the discovery of treatments for neurological and psychiatric disorders, including Parkinson’s and Alzheimer’s diseases. Oragenics is currently conducting Phase IIa trials for its primary candidate, ONP-002, and plans to advance to Phase IIb trials in the US.

    Pharmaceutical Technology·
    US
    OGEN
    -1.49%
    Pharmaceutical Technology·
    US
    OGEN
    -1.49%
    © 2025 Longbridge｜Disclaimer